Castle Biosciences CSTL
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 32nd percentile, 5-year average -30.6x
Near the top of its 5-year range · 85th percentile, 5-year average 1.7x
#3237 of 5329 stocks by PB (1 = cheapest)
Around its usual level · 45th percentile, 5-year average 3.9x
#3003 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.18 | – | 1.67 | 85% (pricier than usual) | #3237 of 5329 (1 = cheapest) |
| PE | -44.46 | -43.01 | -30.57 | 32% (cheaper than usual) | – |
| PS | 2.76 | 2.45 | 3.93 | 45% (cheaper than usual) | #3003 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on CSTL.
Sign in to join the discussion.